- Rising Health Costs Push Some Middle-Aged Adults To Skip the Doc Until Medicare
- Even With Dental Insurance, You Still Could Face a Large Bill
- Don't Forget This: Study Shows Cannabis Exacts a Toll on Your Memory
- Want To Stress Less? Start With These Everyday Habits
- Journalists Shine Light on Out-of-Reach Insurance Prices, AI’s Role in Claims Disputes, and Susie Wiles
- Arizona behavioral health center adds 10 adolescent beds
- The explosion of the Medicare Advantage special needs plan
- The explosion of the Medicare Advantage special needs plan
- We’re Great Thinkers…But Not Rethinkers
- North Star to cut additional jobs
- North Star to cut additional jobs
- Oregon Governor asks PeaceHealth to delay contract switch: 11 things to know
- 6 Optum updates to know from Q1
- Viewpoint: US nursing workforce faces several risks
- The shifting dental hygiene landscape
- 12 dental insurance updates in 30 days
- ‘The 1980s called’: CMS to phase out fax, mail
- ‘The 1980s called’: CMS to phase out fax, mail
- Aligning IT & clinical teams: How to reduce friction and improve communication
- AI tool targets billing gaps at Kentucky system
- AI in pharmacy: Why pilots stall at hospitals
- 37 recent hospital, health system executive moves
- This ASC startup is wiring AI into the fabric of outpatient surgery
- Springer Nature retracts 38 papers over autism dataset
- Intermountain plans new outpatient clinic
- Legacy Health, Regence BCBS face looming contract expiration
- Meet the COOs of the largest DSOs
- Michigan bills target outpatient fees, CON requirements
- Anesthesia group, lawmakers oppose Medicare cuts to non-opioid pain treatment
- Iowa lifts emergency suspension of transplant surgeon’s license
- Vascular center, physician CEO to pay $4M to settle fraud allegations
- In the Affordability Alphabet Soup of the ACA and EHBs, a Link to Higher Premiums Isn’t Clear-Cut
- 5 cardiologists stepping into leadership roles
- New York organizations partner on intellectual, developmental disabilities campus
- Cincinnati hospital acquires outpatient center for $6M
- CMS final rule aims to axe the fax machine, phase out paper mailing
- 24 profitable health systems in 2025
- How 2 CFOs plan for uncertainty
- Heartland Dental expands with Texas affiliation
- MD Anderson opens colorectal cancer center
- SALT Dental Partners adds Washington practice
- 11 dental school updates to know
- 6 health systems seeking revenue cycle executive directors
- Remarks at The SEC Speaks in 2026: From Kitchen Table to Cap Table—Making Capital Formation Work for Small Businesses
- Integrated care model drives 76% depression improvement in 44 days: Study
- Heart Benefits From GLP-1 Drugs Fade After Stopping, Study Finds
- Survey Shows More People Struggling To Afford ACA Insurance
- Up to 155,000 COVID Deaths May Not Have Been Counted, Study Finds
- FDA Drops Plan To Ban Tanning Beds for Minors Nationwide
- Idaho bill proposes consolidating dental regulatory oversight
- Washington hospital charts path to preserve primary care
- 4 DSOs making headlines
- 6 state behavioral health policy updates
- 80% of returning ACA enrollees report higher healthcare costs in 2026
- Fitch downgrades HonorHealth’s credit rating
- NYC Health + Hospitals names dentistry, oral surgery leaders
- Mindray North America Enters Ventilator Market
- Mindray North America Enters Ventilator Market
- LivaNova Receives FDA Premarket Approval for to treat Moderate to Severe Obstructive Sleep Apnea
- LivaNova Receives FDA Premarket Approval for to treat Moderate to Severe Obstructive Sleep Apnea
- Perfuze Receives FDA 510(k) Clearance for Millipede88 Aspiration Catheter
- Perfuze Receives FDA 510(k) Clearance for Millipede88 Aspiration Catheter
- EPA proposes new rule on Ethylene Oxide Emissions: Could Loosen Limits on Medical Device Sterilization
- EPA proposes new rule on Ethylene Oxide Emissions: Could Loosen Limits on Medical Device Sterilization
- With Novo's semaglutide going off patent, Indian drugmakers set to launch their cheaper generics
- Sanofi backs 2 more documentary films about rare blood disorders
- ACIP member's miscommunication on vaccine panel's future adds to confusion after court ruling
- Rhythm's Imcivree scores 'transformative' FDA approval in brain damage-related obesity
- Some Patients With ADHD and Addiction History Missing Out
- Social Media Poses Risks to Children's Mental Health, Review Concludes
- 'Early Bird' Exercisers Get The Most Health Benefits, Study Finds
- Does Closing Your Eyes Help You Hear Better?
- High Blood Pressure Deaths Quadruple Among Young Women, Study Finds
- Meningitis Vaccine Doesn't Protect Gay, Bisexual Men From Gonorrhea, Clinical Trial Concludes
- Oz Escalates Medicaid Fraud Claims Against States After Focus on Minnesota
- Listen: Trump’s NIH ‘Reset’ Is Driving Away Scientists
- ‘How Low Can You Go?’ The Shifting Guidelines for Blood Pressure Control
- Mississippi to fund clinical trials for psychedelic drug
- Lawmakers push bill to boost mental health workforce, diversity
- Florida State partners with behavioral health provider on research
- Utah governor signs hygienist autonomy bill
- UHS CEO: Talkspace deal builds 1st national ‘end-to-end’ behavioral model
- Psychedelic therapy shows no benefit over antidepressants: Study
- What the Health? From KFF Health News: RFK Jr.’s Vaccine Schedule Changes Blocked — For Now
- Verily banks $300M to accelerate AI road map, transitions to independent company
- KFF: ACA plan enrollees report rising costs for 2026 coverage
- Industry Voices—Stop buying AI tools, start designing AI architecture
- CSL warns of supply shortfall, treatment delays for hemophilia gene therapy Hemgenix
- 10K Corewell Health nurses vote to authorize labor strike
- Providence mulling sale of its health plan amid financial pressures
- Fierce Pharma Asia—World's 1st brain chip nod; AZ's cell therapy bet; Astellas-CytomX breakup
- Gut Microbiome May Take Years to Recover From Antibiotic Use
- Prepared Remarks Before SEC Speaks
- The Art and Science of Materiality
- Capital, Choice, and the Pursuit of Happiness: Remarks at The SEC Speaks in 2026
- Novo's Wegovy HD passes muster under FDA national priority voucher program
- Hospital operations begin 2026 with depressed margins amid low volumes, high labor spend
- The Math Behind Eczema Flare-Ups May Finally Add Up
- Male preconception startup Upstream announces donor-matching platform
- Women's health sector could grow to $600B industry by 2030: PwC report
- Democratic senators detail plans to take on 'Big Insurance'
- Both Types Of Diabetes Increase Dementia Risk
- Aldi Recalls Spinach Bites Over Possible Contamination
- Collegium ponies up $650M to gain ADHD drug Azstarys from Corium
- Maryland bill calls for more transparency in pharma's disease awareness campaigns
- After Alfasigma's GSK licensing deal, Lynavoy picks up FDA nod in rare liver disease
- What To Know About Fatty Liver Disease and Why It’s So Common
- Drug Smoking Linked To Surge In Severe Burn Cases
- Thymus Gland Health May Be Key to Long Life and Fighting Cancer
- Premature Menopause Increases Heart Disease Risk
- U.S. Teen Obesity Hits Record Highs While Efforts to Slim Down Drop
- Pesticide Exposure Before Pregnancy Might Risk Newborn Health
- UPDATED: AstraZeneca to build cell therapy manufacturing hub, R&D center in Shanghai
- Many ACA Customers Are Paying Higher Premiums. Most Blame Trump and Republicans, Poll Finds.
- Lawmakers Seek To Protect Crisis Pregnancy Centers as Abortion Clinic Numbers Shrink
- CDMO Axplora to pump $60M into Italian complex API plant
- Pfizer eyes earlier Talzenna use after phase 3 prostate cancer win
- Prodeon Medical FDA 510(k) approved for the Urocross Expander System, a Non-Permanent Retrievable Implant for Treating Benign Prostatic Hyperplasia
- Prodeon Medical FDA 510(k) approved for the Urocross Expander System, a Non-Permanent Retrievable Implant for Treating Benign Prostatic Hyperplasia
- JenaValve Gets FDA Nod for Trilogy Transcatheter Heart Valve (THV) to Treat Aortic Regurgitation (ssAR)
- JenaValve Gets FDA Nod for Trilogy Transcatheter Heart Valve (THV) to Treat Aortic Regurgitation (ssAR)
- Turquoise Health raises $40M to power healthcare contracts, payments
- To tackle healthcare costs, representatives weigh curbs on provider consolidation
- A look at Highmark's specialty pharmacy partnership with Free Market Health
- AD/PD 2026: New data highlight potential cost-effectiveness of confirmatory AD blood testing in U.S. diagnostic pathways
- With downgrade, HSBC casts doubt about Lilly's 'stairway to heaven' trajectory
- TrumpRx's 'world's lowest' drug price claims fall short in global comparison: NYT
- Study Finds Little Proof Cannabis Helps Most Mental Health Conditions
- Meningitis Outbreak Tied to Students Leaves 2 Dead and 11 Sick in England
- J&J, Protagonist's 'game-changer' once-daily psoriasis pill Icotyde nabs FDA approval
- Belly Fat Linked To Heart Failure Risk
- Women More Likely To Survive Cancer Than Men — At A Cost
- BMS brings 'Emily in Paris' star and cancer survivor Ashley Park aboard campaign honoring oncologists
- Sandoz expands biosim collab with Samsung Bioepis, sets sights on Takeda's Entyvio
- Ultra-Processed Foods Linked To Heart Attack, Stroke, Cardiac Arrest
- E. Coli Outbreak Tied To Raw Cheddar Cheese Sickens 7 People
- The Sunshine Vitamin and COVID: New Study Finds Mixed Results for Recovery
- Too Much Smartphone Use Linked to Disordered Eating in Teens
- Shingles Vaccine Protects Heart Failure Patients From Heart Attack, Stroke
- White House Chief of Staff Susie Wiles Diagnosed With Early Breast Cancer
- Gates-backed TerraPower Isotopes blueprints $450M plant to supply next wave of radiopharmaceuticals
- Regulation Crypto Assets: A Token Safe Harbor
- The Last Chapter in the Book of Howey
- Payers, hospitals pan CMS' plan to bring non-network plans to ACA exchanges
- Optum Real and Suki build out collaboration to tackle payment challenges as R1 teams with AI scribe Heidi
- Indiana homes in on life sciences with $1B growth strategy, plan to create 100K jobs
- Moody's: Insurers' 2026 outlook is negative as cost pressures continue to batter industry
- GSK's management of Flovent allowed it to 'game the system': Hassan
- Allina Health to join Sutter Health in $26B proposed transaction
- Norovirus Sickens Close to 200 People on Caribbean Cruise
Costco does not break out their pharmacy sales from their quarter trillion dollar overall sales, but their 614 U.S. warehouses are a major player in pharmaceutical sales:
Costco Says It Will Not Sell Abortion Pill Mifepristone
The company attributes its decision to lack of demand.
By Aldgra Fredly - August 15, 2025Costco Wholesale said on Aug.14 that it would maintain its stance of not selling the abortion pill mifepristone at its U.S. pharmacies due to low customer demand.
Mifepristone is a drug that blocks progesterone, the hormone needed for sustaining pregnancy. The Food and Drug Administration (FDA) approved the drug in 2000 for terminating pregnancy through 10 weeks of gestation, stating on its website that mifepristone is safe when used properly.
“Our position at this time not to sell mifepristone, which has not changed, is based on the lack of demand from our members and other patients, who we understand generally have the drug dispensed by their medical providers,” the retailer said in a statement to multiple news outlets.
The move comes amid campaigns against the pill from faith-based groups, including exchange-traded fund provider Inspire Investing and legal advocacy group Alliance Defending Freedom (ADF).
ADF legal counsel Michael Ross applauded Costco for its decision.
“Retailers like Costco keep their doors open by selling a lifetime of purchases to families, both large and small. They have nothing to gain and much to lose by becoming abortion dispensaries,” Ross said in a statement.
Students for Life America (SFLA) praised the move as “a stunning win for life,” saying that it hopes more companies would follow Costco’s policy.
“Costco Wholesale insists its reason was not based on pressure from groups like ours,” SFLA stated. “We at PLG [pro-life generation] never expected an acknowledgement or public change of corporate heart on record. But we would still like to commend the pro-life movement for speaking sense into Costco Wholesale, resulting in saving the lives of the preborn and women.”
In May, Health Secretary Robert F. Kennedy Jr. ordered the FDA to review mifepristone after an analysis found that nearly 11 percent of women who took the drug experienced serious adverse events, including sepsis and hemorrhaging.
That percentage is higher than the summary figure of less than 0.5 percent in clinical trials reported on the drug label, according to the Ethics and Public Policy Center, which published the analysis.
“I think the new data … is alarming, and clearly it indicates that at the very least, the label should be changed,” Kennedy said on May 14.
In July 2024, New York City Comptroller Brad Lander sent letters to Costco and other retailers to dispense the abortion drug in states where it is legal. In his letter to Costco, Lander warned that failing to do so could raise “significant investor concerns,” noting that the New York City Retirement Systems held $443.9 million in Costco stock.
Several investment advisers and corporate engagement consultants representing investors who held $56 million in Costco stock sent a letter to the retailer urging it not to sell mifepristone.
Their petition received support from thousands of investors and customers.
Costco got lit up by one of their home state Senators for their decision not to sell mifepristone:
https://thehill.com/policy/healthcare/5455913-patty-murray-costco-abortion-pill-mifepristone/
Senate Democrat rips Costco for ‘refusing to sell’ abortion pills
By Steff Danielle Thomas - August 16, 2025Sen. Patty Murray (D-Wash.) hammered Costco on Friday for appeasing “far-right extremists,” after the retailer said earlier this week that its pharmacies would not dispense the abortion medication mifepristone.
“I am deeply alarmed by news reports that Costco is refusing to sell safe, effective, and legal medication for no other reason than to appease the politics of anti-abortion fanatics,” Murray said in a statement following the news. “I refuse to stand by and allow far-right extremists to bully major corporations and dictate what medicine women can or cannot get access to.”
“Where it is legal, retailers and major pharmacies must absolutely make medication abortion available to the women who need it,” the Washington Democrat added.
Costco, in its Thursday announcement, explained that the decision came from a “lack of demand.”
“Our position at this time not to sell mifepristone, which has not changed, is based on the lack of demand from our members and other patients, who we understand generally have the drug dispensed by their medical providers,” the company said, according to Reuters.
The decision comes after CVS and Walgreens announced last year that they received certification to provide the drug in states where abortion remains legal.
Murray pressed Costco to rescind its decision, warning that limiting access to mifepristone, one of two drugs used in medication abortion, is harmful to women’s health.
“Mifepristone is safe and effective—we cannot live in a world where the availability of women’s health care whipsaws back and forth based on the whims of extremists who want to deny women access to basic health care,” she wrote Friday. “I am demanding that Costco immediately reverse course—follow the science and the facts, not the demands of far-right anti-abortion extremists.”
The Supreme Court in a decision last year ruled unanimously that a group of anti-abortion doctors did not have the legal basis to challenge access to the pill.
Despite the ruling, Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drug Administration (FDA) Commissioner Marty Makary are weighing a review of the abortion pill.
Murray questioned Makary during his Senate confirmation hearing on the proposal, as well as President Trump’s moves to gut staff at the FDA.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.
















